Read news on Mocertatug Rezetecan with our app.
Read more in the app
First patient enrolled in GOG-3132/BEHOLD-Ovarian01 phase 3 study evaluating Mocertatug Rezetecan, a novel B7-H4–targeted ADC, in platinum-resistant ovarian cancer - EurekAlert!
